anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention is about maple extracts' use in preparation of free radical scavenging agent and antioxidant. Its characteristic is as followings: in maple extracts, 2,6-2-gallic maple sugar ester is 20-95% in content; Gallicin 1-5%; isodulcitol flavonoid glycoside 1-10% and a little bit of carotenoid, sugar and chlorophyll. Maple extract is more efficient than other free radical scavenging agents and antioxidants. Its ID50 towards the free radical DPPH is no more than 1.0mg/ml. It could be used in various fields as food additives, commodity additives, oxidation resistance, antiaging agent, antiaging agent, sterilization, sulphanilamide and so on. This invention also provides a direction for new drug researches.
Next-generation sequencing (NGS) is changing the paradigm of clinical genetic testing. Unlike highly focused single-gene tests, NGS allows one to examine gene panels, the exome, and the whole genome. With the broad array of molecular tests now available, ordering physicians face the conundrum of selecting the best diagnostic tool for patients with suspected genetic conditions. Single-gene testing is often most appropriate for conditions with distinctive clinical features and minimal locus heterogeneity. NGS-based gene panel testing, which can be complemented with chromosomal microarray analysis (CMA) and other ancillary methods, provides a comprehensive and feasible approach for well documented but genetically heterogeneous disorders. Whole exome sequencing (WES) and whole genome sequencing (WGS) have the advantage of enabling parallel interrogation of most of the genes in the human genome. To some, WES is preferable to previously used methods due to higher diagnostic yield, shorter time to diagnosis, and improved cost-efficiency.

The ability to survey the exome opens up both new opportunities and new challenges. For example, all coding regions of known genes must be analyzed when applying WES to undiagnosed cases with unclear inheritance patterns. Current limitations on variant interpretation capabilities and clinical validity raise questions about the clinical utility of WES as either a stand-alone or a first-choice diagnostic test. Additional challenges include pre- and post-test counseling with appropriate and robust informed consent, bioinformatics analysis setup and validation, variant interpretation and classification, the need for policies and protocols concerning the discovery and reporting of secondary findings unrelated to the presenting indication, a requirement for validation of WES results, assurance of conformation to quality control standards, data storage and accessibility, and reimbursement issues.

Introducing WES into pediatric clinical care of underrepresented populations raises additional issues and considerations of payment coverage, access, and standards of care. Beyond the sheer complexity of the test and its results, clinicians and health systems must address numerous considerations, including: private and public insurance coverage; language and culture differences and their implications for genetic counseling and clinician-patient relationships; ability to access follow-up testing and clinical care; and ability to access appropriate treatment and services. These issues and others will affect not only patients' decision-making regarding WES, but also their post-test needs for patient follow up. The importance of systematically assessing the clinical utility of NGS is critical for determining in which clinical and health care contexts WES will be useful and for commencing research on these considerations.
Pregnant women ≥35 years old would have spontaneous preterm labor. There's no intervention in this group, because it's an Observational Study Model.
Patients receive MBG453 and spartalizumab IV over 30 minutes on Day 1. Patients then undergo stereotactic radiosurgery on Day 8. Courses with MBG453 and spartalizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The present invention provides isolated peptides of Lol p V, a major protein allergen of the species Lolium perenne. Therapeutic peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen of Lol p V. Diagnostic peptides within the scope of the invention bind IgE. The invention also provides modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or diagnosis of sensitivity to Lol p V or an allergen immunologically related to Lol p V in an individual. Therapeutic compositions comprising one or more peptides of the invention are also provided.
The invention discloses a cosmetic application method of biological acid and provides a separate formulation of biological acid substances that is safe and effective, combines nursing and beauty treatment, nourishes skin, defers senility and prevents certain skin diseases, or a preparation that takes biological acid substances as necessary ingredients and is mixed and formulated commonly with emulsion, cream, plaster and powder and other formulations used for cosmetics. The preparation gets multiple effects that can not be reached by the existing cosmetics and not only has the effects of tightening skin and resisting wrinkle, but also resists inflammation and bacteria, protects skin and defers senility. While used for softening and whitening skin, the preparation nourishes skin, prevents certain skin diseases and combines nursing and beauty treatment. While used for maintaining mouth health, the preparation has the functions of diminishing inflammation, fighting ulcer and stopping bleeding. While used for hair styling, the preparation has the function of nourishing hair. And while used as an oral enamel, the preparation has the active functions of diminishing inflammation, improving microcirculation, conditioning intestines and stomach, adjusting body immunity and the like.
PURPOSE: A thrombolytic enzyme isolated from Phellinus baumii is provided to be easily administered without side effects. CONSTITUTION: A thrombolytic enzyme is isolated from Phellinus baumii by hot water extraction. A method for extracting the enzyme comprises: a step of pulverizing Phellinus baumii and suspending in distilled water; a step of incubating at room temperature for 6-8 hours; a step of heating the precipitated sample at 110-130 Deg. C. for 8-10 hours; and a step of heating at 3-10 Deg. C. for 1-3 hours and filtering. A pharmaceutical composition for preventing or treating thrombolytic diseases contains the Phellinus baumii extract or enzyme as an active ingredient. [Reference numerals] (AA) Pulverizing 100g of Phellinus baumii(Mixer); (BB) Placing at room temperature for 6-8 hours; (CC) Thermal treatment at 120 °C for 8-10 hours; (DD) Placing at 4 °C for 2 hours; (EE) Filtering; (FF) Centrifuging supernatant at 10,000 rpm for 20 minutes; (GG) Collecting supernatant(hot water extract)
The patients receive primary rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with TME. To patients with pathological confirmed positive circumferential margin (CRM), postoperative concurrent radiochemotherapy is required that starts in 3 months post operation with capecitabine. Capecitabine and Oxaliplatin (CapeOx) chemotherapy starts in 4 weeks post operation to total of 6 cycles/18 weeks. To patients with pathological confirmed negative CRM, radiotherapy is omitted. The stage III patients receive 8 cycles/6 months CapeOx chemotherapy. The stage II patients with low microsatellite instability (MSI) receive 8 cycles/6 months Capecitabine chemotherapy. The stage II patients with high MSI and stage I patients do not receive adjuvant therapy.
N-Substituted amino acids and dipeptides are valuable intermediates for the preparation of inhibitors of angiotensin converting enzyme (ACE), examples of representatives being enalapril and ramipril. These compounds can be prepared by hydrogenolytic reaction of a primary amine with a ketone, but the known processes are difficult to reproduce and usually still contain considerable amounts of byproducts. The novel process is intended to provide good yields with few byproducts and without additional high costs. The hydrogenolytic reaction is carried out according to the invention with the addition of an organic or inorganic base, with basic aluminium oxide being preferred among the inorganic bases. The formation of one diastereomer is favoured by the use of chiral organic bases. ACE, blood pressure regulators.
Drugs which affect DNA synthesis, such as hydroxyurea, may be potential mutagenic agents. The physician should carefully consider this possibility before administering this drug to male or female patients who may contemplate conception. 

Hydroxyurea capsules can cause fetal harm when administered to a pregnant woman. Hydroxyurea has been demonstrated to be a potent teratogen in a wide variety of animal models, including mice, hamsters, cats, miniature swine, dogs, and monkeys at doses within 1 fold of the human dose given on a mg/m2 basis. Hydroxyurea is embryotoxic and causes fetal malformations (partially ossified cranial bones, absence of eye sockets, hydrocephaly, bipartite sternebrae, missing lumbar vertebrae) at 180 mg/kg/day (about 0.8 times the maximum recommended human daily dose on a mg/m2 basis) in rats and at 30 mg/kg/day (about 0.3 times the maximum recommended human daily dose on a mg/m2 basis) in rabbits. Embryotoxicity was characterized by decreased fetal viability, reduced live litter sizes, and developmental delays. Hydroxyurea crosses the placenta. Single doses of ≥ 375 mg/kg (about 1.7 times the maximum recommended human daily dose on a mg/m2 basis) to rats caused growth retardation and impaired learning ability. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.
PROBLEM TO BE SOLVED: To obtain a surface coating agent which effects the firm adhesion or adsorption of an oleophilic substance and does not separate during operations of formulation such as emulsification, dispersing, mixing and washing by mixing an oleophilic substance which is inert to a solid having a hydrophilic surface and is usually nureactive therewith with a surface-reactive substance reactive with the solid surface and coating a powder with the obtained mixture. SOLUTION: The surface reactive substances used include unsaturated fatty acids, salts thereof, organosilicones, etc., and are exemplified by oleic acid and isostearylamine. The oleophilic substances used are organic ultraviolet absorbers, oil-soluble vitamins, etc., and are exemplified by squalane and octyltriazone. The ratio (by weight) of the surface-reactive substance to the oleophilic substance is 99:10 to 1:90. The solid having a hydrophilic solid is desirably a powder, more desirably a powder for cosmetics and is 0.01-100 μm in size. It is exemplified by starch, silica, kaolin or talc.
OBJECTIVE: Hemophilia carriers (HCs), who are heterozygous for mutations in the clotting factor VIII/clotting factor IX gene (F8 or F9), may have a wide range of clotting factor levels, from very low, similar to afflicted males, to the upper limit of normal, and may experience mental health issues. The purpose of this study was to provide genetic information on mothers of hemophilia patients and to understand the clotting factor activity and phenotype of HCs. Additionally, we aimed to investigate the mental health status of HCs in China.
METHODS: A total of 127 hemophilia mothers, including 93 hemophilia A (HA) mothers and 34 hemophilia B (HB) mothers, were enrolled in this study. Long distance PCR, multiplex PCR, and Sanger sequencing were used to analyze mutations in F8 or F9. Coagulation factor activity was detected by a one-stage clotting assay. The Symptom Checklist 90 (SCL-90, China/Mandarin version) was given to HCs at the same time to assess their mental health.
RESULTS: A total of 90.6% of hemophilia mothers were diagnosed genetically as carriers, with inversion in intron 22 and missense mutations being the most common mutation types in HA and HB carriers, respectively. The median clotting factor level in carriers was 0.74 IU/mL (ranging from 0.09 to 1.74 IU/mL) compared with 1.49 IU/mL (ranging from 0.93 to 1.89 IU/mL) in noncarriers, of which 14.3% of HCs had clotting factor levels of 0.40 IU/mL or below. A total of 53.8% (7/13) of HA carriers with low clotting factor levels (less than 0.50 IU/mL) had a history of bleeding, while none of the HB carriers displayed a bleeding phenotype. The total mean score and the global severity index of the SCL-90 for surveyed HCs were 171.00 (±60.37) and 1.78 (±0.59), respectively. A total of 67.7% of the respondents had psychological symptoms, with obsessive-compulsive disorder being the most prevalent and severe. The pooled estimates of all nine factors were significantly higher than those in the general population (P<0.05).
CONCLUSIONS: The detection rate of gene mutations in hemophilia mothers was 90.6%, with a median clotting factor level of 0.74 IU/mL, and 14.3% of HCs had a clotting factor level of 0.40 IU/mL or below. A history of bleeding was present in 41.2% of HCs with low clotting factor levels (less than 0.50 IU/mL). Additionally, given the fragile mental health status of HCs in China, it is critical to develop efficient strategies to improve psychological well-being.
A patient support system for providing customized user menus. The system comprises a patient support apparatus, a user interface configured to receive input from a user, and a display configured to display user menus or information. The user menus may comprise indicia representative of the operational functions of the patient support apparatus. A controller determines the customized user menu based on usage characteristics, a position of the user interface in proximity to the patient support apparatus, a location of the user interface within a facility, an identification of the user, and/or a patient condition. A touchscreen and/or a mobile device may comprise the user interface and the display. The mobile device may be removably coupled to the patient support apparatus. Methods for improving patient care by providing the customized user menu are also disclosed.
<P>PROBLEM TO BE SOLVED: To provide a method for controlled delivery of a beneficial agent in the peptide- and protein-based drug therapy.  <P>SOLUTION: This composition for administration of a peptide- and protein-based beneficial agent contains a solvent mixture including a hydrophobic solvent and a hydrophilic solvent; a bioerodible polymer; and a beneficial agent. The polymer and the beneficial agent are dissolved. In the composition, the hydrophobic solvent may be benzyl benzoate, the hydrophilic solvent may be benzyl alcohol, and the bioerodible polymer may be a polylactide. The composition has low viscosity, allowing for easy injection through a standard hypodermic needle.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The present invention relates to a medicinal composition effective in preventing and treating atopic dermatitis, and more specifically, to a composition effective in preventing and treating atopic dermatitis, which is extracted from a mixture containing Duchesnea indica (Andr.) Focke, Lithospermum erythrorhizon S. et Z., Sophora flavescens, and the like; and to a pharmaceutical composition comprising the same. The present invention provides a natural composition effective in preventing and treating atopic dermatitis, which is extracted from a mixture containing Duchesnea indica (Andr.) Focke, Lithospermum erythrorhizon S. et Z., Sophora flavescens, green tea, rosin, and unripe fruits of Poncirus trifoliata Rafinesque. In addition, the present invention provides a natural composition effective in preventing and treating atopic dermatitis, which is extracted from a mixture containing, with respect to 100 parts by weight of Duchesnea indica (Andr.) Focke, 50-100 parts by weight of Lithospermum erythrorhizon S. et Z.; 30-70 parts by weight of Sophora flavescens; 30-70 parts by weight of green tea; 30-70 parts by weight of rosin; and 20-50 parts by weight of unripe fruits of Poncirus trifoliata Rafinesque. In addition, the present invention provides a pharmaceutical composition comprising the natural composition effective in preventing and treating atopic dermatitis.
Compounds that selectively inhibit GluN2B -containing N-methyl-D-aspartic acid receptors (NMDARs) are disclosed. In some cases, the compounds selectively target GluN2B over GluN2A, GluN2C, and/or GluN2D. Generally, the compounds possess an enhanced potency to GluN2B at a pH that is more acidic compared to the physiological pH. Pharmaceutical formulations containing one or more of the compounds are also disclosed. Additionally, methods of treating a condition, disorder or disease using the compounds or their pharmaceutical formulations thereof are disclosed. Exemplary conditions, disorders, and diseases relevant to this disclosure include stroke, subarachnoid hemorrhage, cerebral ischemia, cerebral vasospasm, hypoxia, acute CNS injury, spinal cord injury, traumatic brain injury, coronary artery bypass graft, persistent or chronic cough, substance abuse disorder, opiate withdrawal, opiate tolerance, bipolar disorder, suicidal ideation, pain, fibromyalgia, depression, postpartum depression, resting tremor, dementia, epilepsy, seizure disorder, movement disorder, and neurodegenerative disease.
In treatment period 1, subjects will receive oral casopitant 150 mg on Day 1 and 50 mg on Days 2 and 3. In treatment period 2, they will be administered ketoconazole 400 mg once daily on Day 1 to Day 9 and oral casopitant 150 mg on Day 4 and 50 mg on Days 5 and 6. There will be a 14-day washout period between treatment periods 1 and 2.
Analysis of cell-mediated and antibody-mediated immunity to the COVID-19, SARS-CoV-2 virus following treatment with mRNA vaccine, in patients with multiple sclerosis (MS) who are treated with immune modulating medication. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before their first vaccine injection (those who meet inclusion 3a only), 45 (those who meet inclusion 3a or 3b), 90 and 180 days after the first vaccine injection (those who meet inclusion 3a, 3b, or 3c). If they receive a booster vaccine injection, they will also be asked to provide 30 mL of whole blood 28-42 days after the booster injection date. These samples, obtained at Providence St. Vincent Medical Center, will be transferred to the Laboratory of Molecular and Tumor Immunology at the Earle A. Chiles Cancer Research Institute, where the blood will be processed and cryopreserved. Serum samples will be analyzed for the presence and titer of neutralizing antibodies to the SARS-CoV-2 virus. Isolated peripheral blood lymphocytes will be used for analyses of T cell responses to SARS-CoV-2 spike peptides. Responses will be compared to the immune responses of 10 subjects who have been enrolled in the CORVax spike plasmid DNA vaccine study and are subsequently referred to in this protocol as "healthy controls." The unused portion of the samples will be stored for future deep cytokine and genomic analyses if funding becomes available to perform these latter studies.

This study will include 4 cohorts, each will enroll 10 subjects who are being treated with an immunomodulating therapy for MS. The 4 immunomodulating medications selected, because each differs in their mechanisms of action, include ocrelizumab (B-cell lytic), fingolimod (prevents mobilization of B and T cells from peripheral lymphoid organs), natalizumab (blocks transmigration of monocytes, and lymphocytes into the central nervous system), and dimethyl fumarate/diroximel fumarate (reduces inflammation-induce oxidative stress).
BACKGROUND: This study focuses on investigating the risk factors of increased operating room time and patient complication rates after total shoulder arthroplasty cases (both reverse and anatomic). We hypothesize that the use of surgeon-preferred staff will improve operating room efficiency and reduce complication rates while increased staff turnover will decrease efficiency and increase complications.
METHODS: This is a single-center, retrospective study focused on determining the effects of staffing on operating room time and efficiency in total shoulder arthroplasty. The study included patients who underwent total shoulder arthroplasty by a single fellowship-trained orthopaedic surgeon from 2018 to 2023.
RESULTS: Four hundred twenty-three patients were included in the study from August 2018 to April 2023, 264 of which were reverse total shoulder arthroplasty (rTSA) and 159 were anatomic total shoulder arthroplasty (aTSA). In both rTSA and aTSA, the presence of surgeon-preferred staff markedly decreased operating room time. In rTSA, staff turnover increased risk of 90-day complications.
CONCLUSION: Because the presence of surgeon-preferred staff affects operating room time and efficiency, orthopaedic surgeons should train multiple surgical teams so that efficiency is not affected by the loss of personnel during a case. To reduce 90-day complication rates in rTSA, staff breaks and turnover should be minimized as much as possible because this has a direct effect on patient outcomes. Effort from hospital administration and management should be put toward reducing turnover to improve patient outcomes.
Participants in Group 1 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.